We use cookies to ensure that we give you the best experience of our website. If you accept without changing your settings, we assume that you are happy to receive all cookies on the LGC website. However, if you would like to, you can change your cookie settings at anytime.
text.skipToContent text.skipToNavigation

{{ addToCartData.mixPtRmWarning }}

Do you want to proceed?

{{requestQuote.productName}}; {{requestQuote.form.productCode}}

Thank you

We will respond to your enquiry shortly.

Something went wrong, please try again later.

Bulk Order
If not, click 'cancel'. You can also save this item for later.
Cancel
If not, click 'cancel'. You can also save this item for later.
Cancel

Cancer models, research chemicals and reference materials

From early stage drug discovery through to method development, drug substance testing and product release.

 

950x350_TRC_Hero banner-min.jpg

TRC Cancer research chemicals and analytical standards

From kinase inhibitors, apoptosis inducers and cytokine modulators to isotopes and synthetic chemistry building blocks, TRC supports you from target identification to drug development and toxicology.

View range
950x350_ATCC__Hero banner-min.jpg

ATCC Get closer to in vivo

From advanced 3D organoids and immuno-oncology models to the largest global repository of cancer lines, ATCC provides an unparalleled collection of cancer tools for basic research and drug discovery.

Find your cancer model
Mikromol-950x350-min.jpg

Mikromol API and impurity reference standards

Explore our range of reference materials for oncology drugs designed for quantitative analysis. Each comes with a detailed COA providing full transparency of product characterisation.

View range
  • TRC Cancer research chemicals and analytical standards

  • ATCC Get closer to in vivo

  • Mikromol API and impurity reference standards

Cancer is a complex, multifactorial disease characterised by the unrestrained proliferation of cells which invade normal tissues and organs. Hanahan and Weinberg pioneered modern studies of cancer-related genetic aberrations and epigenetic changes in 2011, when they proposed 10 ‘Hallmarks’ for cancer research. These hallmarks include: evading growth suppressors, avoiding immune destruction, enabling replicative immortality, tumour-promoting inflammation, activating invasion and metastasis, inducing angiogenesis, genome instability and mutation, sustaining proliferative signalling and resisting cell apoptosis. Meanwhile, advances in genomics and biochemistry precipitated identification of key drug targets including cyclin-dependent kinases (CDK) and PARP enzymes, telomerases, p53, as well as RTK’s such as EGFR and VEGF. 

 

Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. We provide industry-leading life science tools - from biologically active small molecules to cellular models, such as classical cancer cell lines and 3D screening platforms for the development of personalised medicines. We also supply API and impurity research chemicals as well as primary pharmaceutical reference standards to support your method development and drug batch release.

 

 

 

{{ article.title }}

{{ article.text }}

{{ article.ctaText }}

{{ article.title }}

{{ article.text }}

{{ article.ctaText }}

{{ article.title }}

{{ article.text }}

{{ article.ctaText }}

TRC chemicals are boosting Cancer research

Acquired resistance to EGF receptor inhibitor Osimertinib is a problem for patients with lung cancer. TRC research chemicals were used in an investigation into resistance mechanisms, highlighting a prominent role of AXL/SFK/AKT signalling pathway.

Read the research

Supporting the development of more effective therapies

Acquired resistance to EGF receptor inhibitors remains an issue causing relapse of lung cancers. TRC research chemicals were used in proteomics work to probe the nature of protein networks that assemble around the EGF receptor in resistant cancers.

Read the research

TRC research chemicals were used in this novel treatment study

Decades of research aiming to identify new treatments to reduce mortality rates in metastatic uveal melanoma (UM) are still progressing. TRC research chemicals were used in a trial of a promising novel treatment approach using spheroid models of UM.

Read the research
Punchout session timeout warning

Your punchout session will expire in1 min59 sec.

Select "Continue session" to extend your session.